Actively Recruiting
A Clinical Investigation to Evaluate Microwave Imaging Via MammoWave in a Population-based Screening Program for Early Breast Cancer Detection
Led by Umbria Bioengineering Technologies · Updated on 2026-05-13
10000
Participants Needed
10
Research Sites
24 weeks
Total Duration
On this page
Sponsors
U
Umbria Bioengineering Technologies
Lead Sponsor
L
London South Bank University
Collaborating Sponsor
AI-Summary
What this Trial Is About
Researchers are evaluating MammoWave, a device that uses low-power microwaves instead of X-rays, for early breast cancer detection in women aged 45 to 74. This prospective, multicenter clinical investigation aims to confirm that MammoWave achieves sensitivity greater than 75 and specificity greater than 90 for breast cancer detection among 10,000 volunteers undergoing regular screening programs. The study compares MammoWave results with conventional breast examination methods including mammograms and other radiological or histological tests. Participants will undergo both the standard breast screening exams and the MammoWave exam. The MammoWave exam involves lying prone on a bed while the device collects microwave data from both breasts over about 8 minutes. Data processing uses a special imaging algorithm to produce microwave images and classification results indicating suspicious or non-suspicious findings. The study device contains the same hardware as a CE-marked version but uses updated software. During the study, participants will have conventional breast exams along with the MammoWave exam. Researchers will evaluate MammoWaves sensitivity and specificity during the procedure and analyze detection rates, recall rates, and positive predictive values at baseline. Volunteers will also complete satisfaction questionnaires. The study will monitor breast cancer detection by histological type, size, and breast density. The trial is expected to run until December 2026.
CONDITIONS
Brief Title
A Clinical Investigation to Evaluate Microwave Imaging Via MammoWave® in a Population-based Screening Program for Early Breast Cancer Detection
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Women aged between 45 and 74 years
- Asymptomatic women
- Signed informed consent form before starting any study activity
- Average risk of breast cancer (no known BRCA1, BRCA2, TP53 mutations or previous breast cancer)
- Mammogram performed within the past month or planned on the same or next days as the MammoWave test
- Willingness to comply with the clinical investigation plan and recommendations
You will not qualify if you...
- Women with breast prostheses
- Women with symptoms or signs of suspected breast cancer
- Women with BRCA1, BRCA2, TP53 mutations or previous breast cancer
- Pregnant women
- Women with known occult breast tumor only manifesting in axillary regions
- Women with breast size larger than the largest MammoWave cup size
Research Team
G
Gianluigi Tiberi
S
Sabatino Tiberi
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here